ContraFect Corp CFRXQ

Healthcare Biotechnology

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase, is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its exebacase is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.

GREY:CFRXQ - Post by User

ContraFect Corp

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Apr 27, 2023 11:02am

112 Views

Post# 35416991

CFRX.... thru DTL....just barely

If ....big if.....This gets thru $2.50 with a big volume increase.....it might get my attention....other than that....watch out for continued errosion of the shar price

JMHO

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal